|
Titled "The Potential of Fasting and Diet in the Future of Medicine"
Highlighting the Potential of Ketones - from Fasting, the Ketogenic diet and Pharmaceuticals - to Address Neurological Disease and Improve Brain Health
DENVER, Colo., March 5, 2026 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company developing metabolic drugs for neurological disorders, today announced that Dr. Charles Stacey, Chief Executive Officer of Cerecin, delivered a TEDx talk at TEDxNTU Singapore in October 2025, and the talk is now available to view online.
 
The TEDx talk, “The Potential of Fasting and Diet in the Future of Medicine,” by Dr. Charles Stacey
Titled "The Potential of Fasting and Diet in the Future of Medicine" Dr. Stacey's TEDx talk explores the frontier science of brain energy metabolism, how the brain's high demand for fuel and its vulnerability to energy deficits may contribute to neurological disease, and how ketones, produced during fasting and ketosis, represent an alternative energy source with potential benefit in conditions such as Alzheimer's disease and epilepsy.
The TEDx talk, "The Potential of Fasting and Diet in the Future of Medicine," by Dr. Charles Stacey (TEDxNTU, October 2025) is now available to view online: https://youtu.be/I9ssEspwCFk?si=Wv4TeAw2gbxtVSJU
In the talk, Dr. Stacey describes how the brain, despite representing only ~2% of body weight, consumes up to ~20% of the body's energy, and how imaging and clinical research show that impaired glucose metabolism may be an early and important feature of neurodegenerative and neurological disorders. He explains that when glucose availability declines, the body can shift to producing ketone bodies, derived from fat, which can cross into the brain and be converted into energy, a highly conserved biological pathway.
"If a failing brain is, at its core, an under-fuelled brain, then perhaps the solution is to give it more energy—not by simply adding more glucose, but by restoring brain bioenergetics," said Dr. Charles Stacey, CEO of Cerecin. "This TEDx talk is about the potential of ketones—the physiological emergency fuel the brain—and how translating the biology of fasting into precision pharmacology is opening a new frontier in brain health."
Dr. Stacey also highlights historical and medical observations linking fasting and ketogenic states to seizure control, including early clinical reports that inspired the modern ketogenic diet, and describes how biotech companies at the forefront of modern neuroscience, such as Cerecin, are working to create oral, controlled, and sustainable medicines that deliver the metabolic benefits of ketosis without the burden of strict dietary intervention.
Cerecin is developing a pipeline of neurometabolic assets that target brain energy metabolism. CER-0001 (tricaprilin) and CER-081 are first-in-class ketogenic drug candidates. CER-0001 is in late-stage development for Alzheimer's disease and is also being advanced for rare pediatric epilepsies also known as Developmental and Epileptic Encephalopathies (DEEs). Cerecin is also developing CER-022, an investigational radiolabelled tracer for positron emission tomography (PET) imaging of ketone metabolism.
"Cerecin is at the forefront of a growing field in neuroscience that focuses on energy as a foundational driver of brain function," said Samuel Henderson, PhD, Chief Scientific Officer of Cerecin. Dr. Henderson, who has more than 20 years of experience in neurodegenerative disease research and a PhD in molecular genetics and cell biology from the University of Chicago, leads Cerecin's scientific strategy in neurometabolism and metabolic therapeutics "We are pleased to support Dr. Stacey's effort to share a science-based perspective on ketones, fasting biology, and the potential to develop metabolic therapies that may help address major unmet needs in neurological disease."
Disclaimer
The TEDx talk reflects Dr. Charles Stacey's personal views and perspectives shared in a public forum and does not necessarily represent the views, positions, or strategies of Cerecin. References to scientific concepts are provided for general educational discussion and should not be interpreted as medical advice or as claims regarding the safety or efficacy of any investigational product.
About TEDx
In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TED Talks video and live speakers combine to spark deep discussion and connection. These local, self-organized events are branded TEDx, where **x = independently organized TED.
TEDxNTU 2025, hosted by Nanyang Technological University in Singapore, is one of the region's flagship TEDx events and draws a live audience of several thousand attendees from academia, industry, and the public.
About Cerecin
Cerecin is a biopharmaceutical company focused on the development and commercialization of drugs to improve brain health. Cerecin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of ketosis. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and supported by two partners, Nestlé and Wilmar, one of the world's leading manufacturers and traders of fatty acids and lipids. Bringing together the deep industry expertise of its leadership team and a highly differentiated portfolio, Cerecin is growing its global presence to serve the brain health needs of patients and people across the world.
Media Contact
Cerecin Inc.
info@cerecin.com
www.cerecin.com
Titled "The Potential of Fasting and Diet in the Future of Medicine"
Highlighting the Potential of Ketones - from Fasting, the Ketogenic diet and Pharmaceuticals - to Address Neurological Disease and Improve Brain Health
DENVER, Colo., March 5, 2026 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company developing metabolic drugs for neurological disorders, today announced that Dr. Charles Stacey, Chief Executive Officer of Cerecin, delivered a TEDx talk at TEDxNTU Singapore in October 2025, and the talk is now available to view online.
 
The TEDx talk, “The Potential of Fasting and Diet in the Future of Medicine,” by Dr. Charles Stacey
Titled "The Potential of Fasting and Diet in the Future of Medicine" Dr. Stacey's TEDx talk explores the frontier science of brain energy metabolism, how the brain's high demand for fuel and its vulnerability to energy deficits may contribute to neurological disease, and how ketones, produced during fasting and ketosis, represent an alternative energy source with potential benefit in conditions such as Alzheimer's disease and epilepsy.
The TEDx talk, "The Potential of Fasting and Diet in the Future of Medicine," by Dr. Charles Stacey (TEDxNTU, October 2025) is now available to view online: https://youtu.be/I9ssEspwCFk?si=Wv4TeAw2gbxtVSJU
In the talk, Dr. Stacey describes how the brain, despite representing only ~2% of body weight, consumes up to ~20% of the body's energy, and how imaging and clinical research show that impaired glucose metabolism may be an early and important feature of neurodegenerative and neurological disorders. He explains that when glucose availability declines, the body can shift to producing ketone bodies, derived from fat, which can cross into the brain and be converted into energy, a highly conserved biological pathway.
"If a failing brain is, at its core, an under-fuelled brain, then perhaps the solution is to give it more energy—not by simply adding more glucose, but by restoring brain bioenergetics," said Dr. Charles Stacey, CEO of Cerecin. "This TEDx talk is about the potential of ketones—the physiological emergency fuel the brain—and how translating the biology of fasting into precision pharmacology is opening a new frontier in brain health."
Dr. Stacey also highlights historical and medical observations linking fasting and ketogenic states to seizure control, including early clinical reports that inspired the modern ketogenic diet, and describes how biotech companies at the forefront of modern neuroscience, such as Cerecin, are working to create oral, controlled, and sustainable medicines that deliver the metabolic benefits of ketosis without the burden of strict dietary intervention.
Cerecin is developing a pipeline of neurometabolic assets that target brain energy metabolism. CER-0001 (tricaprilin) and CER-081 are first-in-class ketogenic drug candidates. CER-0001 is in late-stage development for Alzheimer's disease and is also being advanced for rare pediatric epilepsies also known as Developmental and Epileptic Encephalopathies (DEEs). Cerecin is also developing CER-022, an investigational radiolabelled tracer for positron emission tomography (PET) imaging of ketone metabolism.
"Cerecin is at the forefront of a growing field in neuroscience that focuses on energy as a foundational driver of brain function," said Samuel Henderson, PhD, Chief Scientific Officer of Cerecin. Dr. Henderson, who has more than 20 years of experience in neurodegenerative disease research and a PhD in molecular genetics and cell biology from the University of Chicago, leads Cerecin's scientific strategy in neurometabolism and metabolic therapeutics "We are pleased to support Dr. Stacey's effort to share a science-based perspective on ketones, fasting biology, and the potential to develop metabolic therapies that may help address major unmet needs in neurological disease."
Disclaimer
The TEDx talk reflects Dr. Charles Stacey's personal views and perspectives shared in a public forum and does not necessarily represent the views, positions, or strategies of Cerecin. References to scientific concepts are provided for general educational discussion and should not be interpreted as medical advice or as claims regarding the safety or efficacy of any investigational product.
About TEDx
In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TED Talks video and live speakers combine to spark deep discussion and connection. These local, self-organized events are branded TEDx, where **x = independently organized TED.
TEDxNTU 2025, hosted by Nanyang Technological University in Singapore, is one of the region's flagship TEDx events and draws a live audience of several thousand attendees from academia, industry, and the public.
About Cerecin
Cerecin is a biopharmaceutical company focused on the development and commercialization of drugs to improve brain health. Cerecin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of ketosis. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and supported by two partners, Nestlé and Wilmar, one of the world's leading manufacturers and traders of fatty acids and lipids. Bringing together the deep industry expertise of its leadership team and a highly differentiated portfolio, Cerecin is growing its global presence to serve the brain health needs of patients and people across the world.
Media Contact
Cerecin Inc.
info@cerecin.com
www.cerecin.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Cerecin Announces TEDx Talk by CEO Dr. Charles Stacey is Now Available Online
KUALA LUMPUR, Malaysia, March 5, 2026 /PRNewswire/ -- KPJ Healthcare Berhad ("KPJ Healthcare" or "the Group") today launched its first Neuroscience and Stroke Centre of Excellence ("CoE") at Damansara Specialist Hospital 2 ("DSH2"), marking the second Centre of Excellence established under the KPJ Health System ("KPJHS") and expanding the Group's specialised capability in complex neurological and stroke care.
The establishment of the Neuroscience and Stroke CoE advances KPJHS by extending structured clinical pathways into high-acuity specialties that require rapid coordination across emergency care, imaging, intensive care and rehabilitation. This development reflects the Group's continued focus on strengthening specialised services while maintaining consistent standards of care across its network.
The Centre brings together multidisciplinary teams across neurology, neurosurgery, emergency medicine, radiology, intensive care and rehabilitation within a coordinated system designed for neurological emergencies. This integrated model enables faster decision-making, timely intervention and continuity of care throughout the critical stages of stroke treatment and recovery.
Datuk Syed Mohamed Syed Ibrahim, President and Chief Executive of Johor Corporation (JCorp) and Chairman of KPJ Healthcare University said, "The establishment of this Centre of Excellence marks another important step in our journey to build the KPJ Health System as a fully integrated ecosystem that connects hospitals, education and research. By strengthening clinical protocols, advancing innovation and continuously benchmarking ourselves against global leaders, we are building a system that delivers better outcomes for patients while remaining future-ready. Our aspiration is clear: to ensure KPJ Healthcare not only keeps pace with global standards, but steadily positions itself among the institutions shaping the future of healthcare in the region."
Chin Keat Chyuan, President and Managing Director of KPJ Healthcare said, "This Centre strengthens our operational capability in managing complex neurological emergencies within a coordinated system framework. By aligning specialised facilities, clinical expertise and structured governance, we ensure timely intervention and continuity of care in line with our commitment to Care for Life."
The DSH2 CoE delivers an integrated stroke pathway from immediate activation in the Emergency Department through hyperacute intervention, critical care and structured early rehabilitation. The Centre provides 24-hour access to advanced CT and MRI imaging, as well as mechanical thrombectomy services to remove blood clots in acute stroke cases. DSH2 has achieved door-to-needle thrombolysis, a clot-dissolving treatment for eligible patients, within 60 minutes through coordinated hyperacute workflows aligned to international benchmarks.
The Centre aligns its protocol-driven stroke and critical care with evidence-based medicine and Mayo Clinic Care Network ("MCCN") standards, including adoption of the CERTAIN ("Checklist for Early Recognition and Treatment of Acute Illness and Injury") critical care framework to support standardised ICU workflows and structured clinical oversight in managing complex neurological emergencies including stroke Through its MCCN membership, DSH2 also has access to clinical benchmarking resources and knowledge exchange that support continuous quality improvement in stroke and neurological care.
Rehabilitation begins early within the acute phase and involves personalised neurorehabilitation supported by standardised clinical assessments, a dedicated Activities of Daily Living ("ADL") Lab and robotic-assisted therapy to support functional recovery and long-term independence. A dedicated Stroke Nurse Navigator provides a single point of coordination for patients and families, ensuring continuity from emergency admission through rehabilitation and post-discharge follow-up.
Beyond acute stroke care, the Centre strengthens subspecialty capability in movement disorders and Parkinson's disease, supported by neurology and neurosurgery expertise and future Deep Brain Stimulation capability. SMART Ward features and PACS-enabled digital integration support real-time monitoring, documentation and multidisciplinary coordination.
The CoE framework serves as a reference model for neuro and stroke service development across the KPJ network. Beyond clinical services, the Centre supports structured education and training initiatives and contributes to clinical research in neurology and stroke management under KPJHS. It also supports the ongoing development of digitally enabled stroke care solutions in collaboration with KPJ Healthcare University, reinforcing the Group's commitment to advancing innovation in neurological care.
The launch forms part of KPJ Healthcare's roadmap to establish 15 Centres of Excellence by 2030 under KPJHS.
ENDS
About KPJ Healthcare Berhad
KPJ Healthcare operates 30 hospitals across Malaysia and four Ambulatory Care Centres, serving 3.3 million patients annually with 1,491 medical consultants. Nineteen hospitals are accredited by MSQH and four by JCI. As Malaysia's first private healthcare provider to establish an Academic Health System, KPJHS integrates practice, education and research & innovation to drive clinical excellence and patient experience. Beyond hospitals, KPJ Healthcare operates Klinik Waqaf An-Nur (KWAN) clinics, dialysis centres and mobile clinics nationwide, and offers more than 40 academic programmes at KPJ Healthcare University (KPJU). KPJ Healthcare has been a constituent of the Bursa Malaysia FTSE4Good Index since 2016.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
KPJ Healthcare Launches First Neuroscience and Stroke Centre of Excellence at DSH2 under KPJ Health System
